What is Atea Pharmaceuticals Book Value per Share?
Atea Pharmaceuticals's book value per share for the quarter that ended in Dec. 2024 was $5.20.
During the past 12 months, Atea Pharmaceuticals's average Book Value Per Share Growth Rate was -21.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Atea Pharmaceuticals was -15.30% per year. The lowest was -15.30% per year. And the median was -15.30% per year.
During the past 7 years, the highest P/B Ratio of Atea Pharmaceuticals was 12.95. The lowest was 0.34. And the median was 0.53.
Warning Sign:
Atea Pharmaceuticals Inc stock PB Ratio (=0.57) is close to 2-year high of 0.59.
Atea Pharmaceuticals Book Value per Share Historical Data
The historical data trend for Atea Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Atea Pharmaceuticals's Book Value per Share
For the Biotechnology subindustry, Atea Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atea Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Atea Pharmaceuticals's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Atea Pharmaceuticals (NAS:AVIR) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Atea Pharmaceuticals Book Value per Share Related Terms
Thank you for viewing the detailed overview of Atea Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVIR has been successfully added to your 